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Abstrakt 
 
Universita Karlova v Praze 
Farmaceutická fakulta v Hradci Králové 
Katedra farmakologie 
 
Kandidát: Lucie Brátová 
Školitel: PharmDr. Marie Vopršalová, CSc. 
Název diplomové práce: Vliv reaktivátorů acetylcholinesterázy na cholinesterázy a 
cholinoreceptory 
 
Diplomová práce se zabývá efektem oximů na muskarinových receptorech. V první 
půlce teoretické části je popsán autonomní nervový systém, hlavní receptory a funkce 
acetylcholinesterázy. Druhá půlka shrnuje důležité nervové plyny, otravu organofosfáty 
a její léčbu. Závěrem představuje oximy a jejich mechanismus účinku. 
Praktická část popisuje metodiku experimentů na potkaních srdečních síních. Jak in 
vitro, tak in vivo studie prokázaly efekt oximů na M2 receptory a jejich antimuskarinové 
vlastnosti. In vivo experimenty byly zaměřeny na protichůdné účinky oximů – inhibice 
AChE vysokými koncentracemi oximu a inhibice muskarinových receptorů nízkými 
koncentracemi toho samého oximu. 
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Abstrakt 
 
Charles University in Prague 
Phaculty of Pharmacy in Hradec Králové 
Department of Pharmacology 
 
Candidate: Lucie Brátová 
Supervisor: PharmDr. Marie Vopršalová, CSc. 
Title of Diploma Thesis: The effect of acetylcholinesterases reactivators on the 
cholinesterases and cholinoreceptors 
 
This thesis is concerned with the effects of oximes on the muscarinic receptors. In the 
first half of the theoretical part there is a description of the autonomic nervous system, 
main receptors and action of acetylcholinesterase (AChE). The second part summarizes 
important nerve gases, organophosphate poisoning and its treatment and finally 
introduces oximes and their mechanisms of action. 
The practical part shows the metodology of experiments on the atria tissues in the rat. 
Both in vitro and in vivo procedures demonstrated effect of oximes on the M2 receptors 
and their antimuscarinic properties. The in vivo studies were focused on the two 
contradictory effects – the inhibition of AChE and the inhibition of muscarinic receptors 
by the very same compound.  
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I. Introduction 
 
The increased international concern about the threat of military and terroristic use of 
nerve agents and the fact that oximes are not always very effective as reactivators and 
none of them can be regarded as a broadspectrum antidote, those are the main reasons 
why futher research and investigation are being conducted. The experiments confirmed 
a hypothesis that not only a well-known cholinesterase reactivation activity of oximes 
but also their multiple effects - on muscarinic and nicotinic receptors – may play a key 
role in their life-saving effects. This has made the research field much wider. 
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II. Review of literature 
 
A. The nervous system 
 
The nervous system can be divided into two anatomical parts: the central nervous 
system (CNS), which is composed of the brain and spinal cord, and the peripheral 
nervous system, which includes the rest of the neurons located outside the brain and 
spinal cord. We can subdivide those nerves into efferent division, the neurons that carry 
signals to the peripheral tissues, and the afferent division, the neurons that bring 
information from the sensory receptors at the periphery to the CNS. Efferent fibers are 
further divide into two functional groups – somatic and autonomic, also called visceral 
or vegetative, system. The somatic efferent neurons are involved in the voluntary 
control of function such as contraction of the skeletal muscle. On contrary to autonomic 
system, single myelinated motor neuron, originating in the CNS, travels directly to 
skeletal muscle without the mediation of ganglia. The efferent nerves of the involuntary 
system supply all innervated structures of the body except skeletal muscle, and this is 
provided by autonomic system (Howland, Mycek et al. 2006). 
Autonomic nerve fibers affect the target organs by a two-neuron pathway. The cell 
bodies of the peripheral neurons are grouped together to form ganglia. The first neuron, 
preganglionic, passing from the CNS to the ganglia synapses with a second 
(postganglionic) neuron that innervates the target organ. The preganglionic fibers are 
slow-conducting (class B and C) which release acetylcholine (Nachon, Asojo et al.). 
The final motor neurons from the ganglia to the tissues, the postganglionic fibers, are 
also slow-conducting, unmyelinated class C fibers (Golan 2005; Petersen 2007). 
 
Autonomic system is classically divided into two subsystems: sympathetic nervous 
system mediated by noradrenalin and parasympathetic nervous system mediated by 
acetylcholine.  
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1. “Fight or flight” response 
 
The sympathetic nervous system is also known as the thoracolumbar system, because its 
preganglionic fibers arise from the first thoracic segment to the second or third lumbar 
segment of the spinal cord (Golan 2005). Postganglionic (adrenergic) fibers release the 
neurotransmitter noradrenalin. The adrenal medullae release the hormone adrenaline, 
and also some noradrenalin, into the blood stream rather than directly on to effectors’ 
cells. Some sympathetic nerves that innervate the blood vessels of muscles, sweat 
glands and hair follicles in the skin release acetylcholine instead of noradrenalin 
(Petersen 2007). Sympathetic division is to some degree continually active but the main 
property is to cope with stressful situations such as trauma, fear, hypoglycemia, cold or 
exercise. The effect of sympathetic output is to increase the heart rate and the blood 
pressure, to mobilize energy stored in body, and to increase blood flow to skeletal 
muscle and the heart while reducing it from the skin and internal organs (Howland, 
Mycek et al. 2006). 
 
 
2. “Rest and digest” response 
 
The preganglionic neurons of the parasympathetic system come from both brainstem 
and sacral segments of the spinal cord – thus, the parasympathetic system is also called 
the craniosacral system. There are no paravertebral ganglia in this system, nearly all of 
the parasympathetic ganglia lie in or near the organs they innervate. It usually acts to 
oppose or balance the action of the sympathetic division and is generally dominant over 
the sympathetic system in ―rest and digest‖ situations. It is necessary to say that 
parasympathetic system never discharges in all innervated organs; instead, discrete 
parasympathetic fibers are activated separately in order to prevent massive, undesirable 
unpleasant symptoms and to affect specific organs, such as stomach or eye (Howland, 
Mycek et al. 2006; Petersen 2007). 
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3. Non-adrenergic non-cholinergic (NANC) neurones 
 
There are many autonomically innervated tissues (e.g. in the cardiovascular, respiratory 
and urinary systems), where neurotransmitters other than noradrenalin and acetylcholine 
are released from postganglionic motor neurons to modify the activity of effector 
organs. There is an evidence that these compounds (e.g. peptides, ATP, NO or opioids) 
are released either along with the classical transmitter as a co-transmitters, primary 
transmitters, or as neuromodulators (Petersen 2007). 
 
 
B. Cholinergic system 
 
The cellular actions of acetylcholine are mediated by two structurally diverse families 
of membrane-bounded proteins, the nicotinic (nAChR) and the muscarinic (mAChR) 
receptors. These receptors, both of which are composed of multiple subtypes, are 
expressed pre- and postsynaptically and have discrete distributions throughout the 
central and peripheral nervous systems.  
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Table 1: Muscarinic acetylcholine receptor subtypes (Rang and Dale 2007)
Characteristic M1 (“neural”) M2 (“cardiac”) M3 (“glandular/smooth muscle”) M4 M5 
Main locations CNS: cortex, hippocampus 
Glands: gastric, salivary, 
etc. 
Heart: atria 
Smooth muscle: GI tract 
CNS: widely distributed 
Exocrine glands: gastric, salivary,  
etc. 
Smooth muscle: GI tract, eye 
Blood vessels: endothelium 
? Lung CNS:  
cortex, striatum 
CNS: very  
localized  
expression  
in substantia nigra 
Salivary glands 
Iris/ciliary muscle 
Cellular response ↑ IP3, DAG 
Depolarization 
Excitation  
↑ K+ conductance 
↓ cAMP Inhibition 
↓ Ca2+ conductance 
↑ K+ conductance 
↑ IP3 Stimulation 
↑ (Ca2+)i 
As M2 As M3 
Functional 
response 
CNS excitation 
(?memory) 
Gastric secretion 
Cardiac inhibition 
Neural inhibition 
Central muscarinic 
effects, e.g. tremor, 
hypothermia 
Gastric, salivary secretion 
GI smooth muscle contraction 
Ocular accommodation 
Vasodilatation 
Enhanced  
locomotion 
Not known 
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Table 2: Nicotinic acetylcholine receptor subtype (Rang and Dale 2007)
Characteristic Muscle type Ganglion type CNS type 
Main synaptic location Skeletal neuromuscular junction:  
mainly postsynaptic 
Autonomic ganglia: mainly  
postsynaptic 
Many brain regions: pre- and  
postsynaptic 
Membrane response Excitatory 
Increased cation permeability  
(mainly Na
+
, K
+
) 
Excitatory 
Increased cation permeability  
(mainly Na
+
, K
+
) 
Pre- and postsynaptic excitation 
Increased Ca
2+
 permeability 
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1. Nicotinic receptors 
 
All nicotinic receptors (Table 2) are pentameric structures which function as ligand-
gated ion channels and are responsible for fast excitatory synaptic transmission.  They 
fall into three main classes: the muscle, ganglionic and CNS types. Muscle receptors 
can be found at the skeletal neuromuscular junction, ganglionic receptors are 
responsible for transmission at sympathetic and parasympathetic ganglia, CNS-type 
receptors are widespread in the brain and are quite heterogeneous. They differ in 
molecular structure and thus they have distinct pharmacological properties (Rang and 
Dale 2007). 
The five subunits that form the receptor-channel complex are similar in structure. The α 
subunits possess two adjacent cysteines essential for acetylcholine binding, whereas the 
non-α referred to as β, γ, ε, or δ do not (Dani and Bertrand 2007). But there might be 
several new nAChR subunit genes still uncovered in the human genome. 
A lateral cross section of the nAChR displays an extracellular water-filled vestibule and 
extends from the membrane surface into the synaptic cleft (Dani and Bertrand 2007).  
 
 
2. Muscarinic receptors 
 
The muscarinic receptors belong to the family of G-protein-coupled receptors. The G 
proteins, consisting of one α-, β- and γ-subunit, are subdivided into Gs, Gi/o, Gq and G12 
depending on the primary sequence homology of their α-subunits. The muscarinic 
receptor subtypes couple differentially to the G proteins, and the subunits of G proteins 
activate distinct cellular pathways (Giglio and Tobin 2009). 
The muscarinic receptors are considered to comprise five subtypes - muscarinic M1, 
M2, M3, M4 and M5 receptors, but only four have been distinguished functionally and 
pharmacologically (Table 1). The pharmacological classification of these receptor types 
relies on the limited selectivity of certain agonists and antagonists that can distinguish 
between them (Rang and Dale 2007). 
M1-receptors are found mainly on CNS and peripheral neurons, gastric parietal cells 
and significant levels have been reported also in salivary glands (Tobin, Giglio et al. 
2002).  They mediate excitatory effects, for example the slow muscarinic excitation 
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mediated by acetylcholine in sympathetic ganglia and central neurons. This excitation is 
produced by a decrease in K
+
 conductance, which causes membrane depolarization. 
Deficiency of this kind of acetylcholine-mediated effect in the brain is possibly 
associated with dementia. M1-receptors are also involved in the increase of gastric acid 
secretion following vagal stimulation (Tobin, Giglio et al. 2009). 
M2-receptors occur in the heart, and also on the presynaptic terminals of peripheral 
and central neurons. They exert inhibitory effects, mainly by increasing K
+
 conductance 
and by inhibiting calcium channels (Rang and Dale 2007). M2-receptor activation is 
responsible for the vagal inhibition of the heart, as well as the presynaptic inhibition in 
the CNS and periphery. 
M3-receptors produce mainly excitatory effects, i.e., stimulation of glandular 
secretions (salivary, bronchial, sweat, etc.) and contraction of visceral smooth muscle. 
M3-receptors also mediate relaxation (mainly vascular) of smooth muscle, which results 
from the release of nitric oxide from neighbouring endothelial cells (Golan 2005).  
The odd-numbered members of the group (M1, M3, M5) act through the inositol 
phosphate pathway, while the even-numbered receptors (M2, M4) act by inhibiting 
adenylate cyclase and thus reducing intracellular cAMP (Rang and Dale 2007). 
 
The subtypes of the receptor population interact on neuronal as well as on non-neuronal 
cells in regulation of autonomic responses. 
 
 
a) Neuronal muscarinic receptors 
 
The prejunctional inhibitory muscarinic receptor was for a long time considered to be 
the M2 subtype. On the other hand, binding studies have indicated the best correlation 
to the muscarinic M4 receptor and not the muscarinic M2 receptor in some organs. 
Therefore, there are two distinct subtypes on prejunctional terminals in several 
peripheral tissues, including smooth muscle and glandular tissue. 
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b) Non-neuronal muscarinic receptors 
 
It has been proved that muscarinic M3 receptors mediate most postjunctional effects. 
However, postjunctional muscarinic M2 receptors also occur, commonly co-localised 
with the muscarinic M3 receptor. Studies in several species, including man, indicate 
synergistic effects of M2 and M3 receptors in controlling smooth muscle contraction 
(Tobin, Giglio et al. 2009). 
 
 
 
 
Figure 1: Adapted from 
http://thebrain.mcgill.ca/flash/a/a_06/a_06_m/a_06_m_mou/a_06_m_mou.html 
Figure shows the neuromuscular junction, how the acetylcholine is synthetized, stored, 
released and broken down. It also describes the structure of the nicotinic receptor. 
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C. Cholinoesterases (ChEs) 
 
There are two distinct ChEs for transmitter hydrolysis: acetylcholinesterase (EC 3.1.1.7, 
AChE) and butyrylcholinesterase (EC. 3.1.1.8, BuChE) (Adler, Manley et al. 2004). 
While AChE is found in cholinergic neurons, it is distributed more widely than 
cholinergic synapses. It is highly concentrated at the postsynaptic end-plate of the 
neuromuscular junction. Furthermore, it also occurs in red blood cells. BuChE is 
synthesized primarily in the liver and is found in liver and plasma. AChE and BuChE 
can be distinguished by the relative rates of acetylcholine (ACh) and butyrylcholine 
hydrolysis, by the affinity to various substrates and by effects of selective inhibitors 
(Goodman and Brunton 2008). AChE is quite specific for ACh and closely related 
esters such as methacholine. BuChE has broader substrate specificity than AChE but is 
not particularly associated with cholinergic synapses, and its physiological function is 
unclear. 
Both consist of globular catalytic subunits, which are linked to collagen-like proteins or 
to glycolipids to the cell membrane or the basement membrane at various sites, 
including cholinergic synapses (and erythrocyte membrane, where the function of the 
enzyme is still unknown) (Rang and Dale 2007). 
 
 
1. Acetylcholinesterase 
 
AChE is capable of hydrolyzing about 4 x 10
5
 molecules of ACh per enzyme molecule 
per minute, and so its turnover time of 150 microseconds makes it one of the most 
efficient hydrolytic enzymes known (Golan 2005). Inhibition of AChE results in a 
progressive accumulation of ACh, especially during periods of repetitive stimulation 
(Adler, Manley et al. 2004). Cholinesterases are characterized as the main enzymes 
involved in the toxic effect of organophosphorus nerve agents (Bajgar 2004).  
AChE exists in two general classes of molecular forms: simple homomeric oligomers of 
catalitic subunits (i.e., monomers, dimers, and tetramers) and heteromeric associations 
of catalytic subunits with structural subunits (Perrier, Cousin et al. 2000). The 3-D 
structures of AChE show the active center to be almost centrosymmetric to each subunit 
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and is located at the base of a narrow gorge about 20 Å in depth (Sussman, Harel et al. 
1991).  
 
2. Effects of anticholinesterase drugs 
 
Cholinesterase inhibitors affect peripheral as well as central cholinergic synapses. The 
characteristic pharmacological effects of the anti-ChE agents are primarily due to the 
prevention of hydrolysis of ACh by AChE at the sites of cholinergic transmission. 
 
 
a) Effects on autonomic cholinergic synapses 
 
These mainly reflect an enhancement of ACh activity at parasympathetic postganglionic 
synapses (i.e., increased secretion from salivary, lacrimal, bronchial and gastrointestinal 
glands; increased peristaltic activity; bronchial constriction; bradycardia and 
hypotension; pupillary constriction; fixation of acommodation for near vision; fall in 
intraocular pressure). 
Acute anticholinesterase poisoning causes severe bradycardia, hypotension and 
difficulty in breathing. In combination with a depolarising neuromuscular block, and 
central effects, the result may be fatal. 
 
 
b) Effects on the neuromuscular junction 
 
Anticholinesterase agents increase the twitch tension of a muscle stimulated via its 
motor nerve. Inhibiting AChE gives the ACh molecules a greater chance of finding a 
vacant receptor before being destroyed. In myastenia gravis, transmission fails because 
there are too few ACh receptors, and cholinesterase inhibition improves transmission. 
In large doses, such as in organophoshourus poisoning, anticholinesterase drugs initially 
cause twitching of a muscle. Later, paralysis may occur due to depolarisation block, 
which is associated with the cumulation of ACh in the plasma and tissue fluids (Rang 
and Dale 2007). 
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c) Neurotoxicity of organophosphates 
 
Tertiary compounds, such as physostigmine, and the non-polar organophosphates 
penetrate the blood-brain barrier freely and affect the brain. The result is an initial 
excitation, which can result in convulsions, followed by depression, which can cause 
unconsciousness and respiratory failure. These central effects result mainly from the 
activation of muscarinic receptors (mAChRs) (Rang and Dale 2007), and are 
antagonised by atropine. 
Many organophosphates can cause a severe type of peripheral nerve demyelination, 
leading to progressive weakness and sensory loss. Similar effect could be presumed in 
the CNS. 
 
 
D. Organophosphorus Compounds  
 
Shortly before and during World War II, a new class of highly toxic chemicals, the 
organophosphates, was developed first as agricultural insecticides and later as potential 
chemical warfare agents. It was Gerhard Schrader who first defined the structural 
requirements for anti-ChE activity after synthesizing approximately 2000 compounds 
(Goodman and Brunton 2008). 
 
 
1. Insecticides 
 
One of the compounds in the early series, parathion (a phosphorothionate) later became 
the most widely used insecticide of this class. The reason is because of its low volatility 
and stability in aqueous solution. Parathion itself is inactive in inhibiting AChE in vitro; 
paraoxon is the active metabolite. Other insecticides possessing the phosphorothioate 
structure have been widely employed for home, garden and agricultural use. These 
include diazinon and chlorpyrifos (Goodman and Brunton 2008). 
Malathion, also possessing thionophosphorus bond, is a precursor as well. The 
detoxication reaction is much more rapid in mammals and birds than in insects. In 
recent years, malathion has been employed in aerial spraying of relatively populous 
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areas for control of Mediterranean fruit flies and mosquitoes that harbor and transmit 
viruses harmful to human beings, such as the West Nile encephalitis virus. Evidence of 
acute toxicity arises only with suicide attempts or deliberate poisoning (Bardin, van 
Eeden et al. 1994). 
 
 
2. Nerve agents (NAs) 
 
The first organophosphorus nerve agents, tabun (GA) and sarin (GB), were developed 
in the 1930s by Gerhard Schrader, later in 1944 was synthetized even more toxic soman 
(McNamara, Pulido-Rios et al. 2009). Together with VX, developed after World War II 
in the United Kingdom, these compounds have emerged as the major nerve agents 
(Jokanovic 2009). Simple and inexpensive to make, easy to disperse, difficult to detect, 
feared by the public, and with a potential lethality to kill hundreds in one attack, NAs 
are nearly the ideal terrorist weapon. Insidious employment of these agents has occurred 
in warfare and terrorism attacks (e.g. Tokyo subway attack) (Nozaki, Aikawa et al. 
1995).  
 
Nerve agents can be divided into two groups – G-series agents (abbreviation of 
―German‖): GA (tabun), GB (sarin), GD (soman), GF (cyclosarin) and V series agents 
(abbreviation of ―venom‖): VX and VR. The G agents are viscous colorless liquids of 
high volatility and inexpressive odor. V agents are colorless, susceptibly less volatile 
liquids of a high stability (Bajgar 2004).
 
 
The general formula for this class of cholinesterase inhibitors is presented in Figure 3. A 
great variety of substituents is possible: R1 and R2 may be alkyl, alkoxy, aryloxy, 
amido, thio, or other groups, and X, the leaving group, a conjugate base of a weak acid, 
is found as a halide, cyanide, thiocyanate, phenoxy, thiophenoxy, phosphate, 
thiocholine, or carboxylate group. 
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Figure 3 
 
 Tabun contains a cyanide group. Sarin and soman, which contain a fluorine substituent 
group, are methylphosphonofluoridate esters. These nerve agents contain a C–P bond 
that is almost unique in that it is not found in organophosphate pesticides. This C–P 
bond is very resistant to hydrolysis. VX contains a sulfur and is an 
alkylphosphonothiolate.  
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Figure 4: Organophosphorus nerve agents 
 
Nerve agents react rapidly with a serine hydroxyl group in the active site of AChE with 
the formation of a phosphate or phosphonate ester. The phosphorylated enzyme 
regenerates very slowly leaving the enzyme inaccessible for its physiological substrate 
ACh. Both organophosphorus (OP) pesticides and nerve agents loose their acyl radicals 
when they react with AChE, ChE and carboxylesterase (CarbE). After binding to ChE, 
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the phosphoryl residues of soman, sarin, tabun and VX undergo an intramolecular 
rearrangement with subsequent loss of one phosphoryl group. This reaction is known as 
aging defined as non-enzymatic time-dependent loss of one alkyl group bound to the 
phosphorus which leads to a stable non-reactivatable form of phosphorylated AChE 
(Sidell and Groff 1974; Jokanovic 2009). Aging of nerve agents such as soman is very 
fast and occurs in a few minutes, while aging of pesticides such as paraoxon or ethyl-
dichlorvos can take hours to days (Nachon, Asojo et al. 2005). 
 
 
Figure 5. Interaction of esterases (E) (such as acetylcholinesterase) with 
organophosphorus compounds. Reaction 1 shows interaction of organophosphate 
molecule with the serine hydroxyl group at the active site of esterase via formation of an 
intermediate Michaelis–Menten complex leading to phosphorylated enzyme (Reaction 
2). Reaction 3 is a spontaneous reactivation of inhibited esterase which occurs very 
slowly for most OP. Reaction 4, known as ―aging‖, represents time-dependent loss of 
one alkyl group (R) bound to the phosphorus (Jokanovic 2009). 
 
 
a) Clinical signs and symptoms of nerve agent 
intoxication 
 
The effects of acute intoxication by anti-ChE agents are manifested by muscarinic and 
nicotinic signs and symptoms and, except for compounds with extremely low lipid 
solubility, by signs referable to the CNS. The syndrom of NA intoxication is therefore a 
constellation of parasympathetic effects, neuromuscular junction (NMJ) function 
failure, and impairment of CNS function. In a roughly dose-dependent manner, this 
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translates primarily into miosis, blurred or dim vision with headache, tearing, 
bronchoconstriction, excessive upper and lower respiratory secretion, nausea with 
vomiting or diarrhea, fasciculations progressing to paralysis, altered mental status, loss 
of consciousness, seizures and apnea (Leikin, Thomas et al. 2002). Duration of the 
effects is determinated largely by the properties of the compound: its lipid solubility, 
whether or not it must be activated to form the oxon, the stability of the 
organophosphorus bond, and whether or not ―aging‖ of the phosphorylated enzyme has 
occurred (Goodman and Brunton 2008). The particular symptoms and signs a patient 
displays are a product of the dose he has received and the route of exposure. Exposure 
may come via inhalation of vapor, absorption by the conjuctiva, absorption by the skin 
or mucous membranes, wound absorption, or absorption by the gut (Cannard 2006). In 
general, vapor inhalation is the most lethal route, largely because the dose can be so 
rapidly delivered to the systemic circulation and CNS. Death can ensue within seconds 
to minutes. However, because of lack of a depot effect following inhalation, if one can 
survive the initial 20-30 min of vapor exposure without respiratory failure, the chance 
of survival is very high (Nozaki, Aikawa et al. 1995). 
Delayed symptoms appearing after one to four days are marked by persistent low blood 
cholinesterase and severe muscle weakness (Marrs 1993). A delayed neurotoxicity also 
may be evident after severe intoxication.  
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Clinical severity  
 
Symptom category 
Mild Moderate Severe 
Autonomic  
(parasymathetic) 
Miosis, dim or  
blurred vision, 
eye  
pain or headache,  
tearing, 
rhinorrhea  
or sialorrhea, 
mild  
wheezing, local  
sweating (skin  
exposure) 
Bronchorrhea,  
dyspnea,  
nausea/vomiting,  
abdominal cramps,  
incontinence, mild  
arrhythmias 
Copious secretions,  
severe airway  
resistance, 
dangerous 
arrhythmias 
NMJ None Mild weakness,  
fasciculations 
Flaccid paralysis,  
apnea 
CNS None Irritability, anxiety,  
impaired judgment  
or memory, slurred  
speech 
Altered mental 
status, 
loss of 
consciousness, 
seizures, central  
apnea 
 
Table 4: Clinical signs and symptoms of nerve aget intoxication (Cannard 2006) 
  
Clinical diagnosis is relatively simple and is based on medical history and 
circumstances of exposure as well as the presence of symptoms of poisoning. 
Confirmation of diagnosis can be made by measurement of red blood cell AChE activity 
or plasma ChE activity, which are accepted as biomarkers of exposure to OP 
compounds and carbamates (Jokanovic and Stojiljkovic 2006). 
 
 
b) Treatment of organophosphorus poisoning 
 
(1) Prophylaxis 
  
Prophylaxis is an approach when an exposure to organophosphates is supposed. There 
are various options available. 
(1) First and well known is an administration of inhibitors that are able to inhibit AChE 
reversibly and after recovery, normal AChE serves as the enzyme source. Examples of 
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such inhibitors are carbamates (pyridostigmine, physostigmine, aminostigmine). 
Pyridostigmine was introduced to some armies as the most promising prophylactic drug, 
especially against soman (Anderson, Harris et al. 1992). (2) Another possibility is to 
administrate an enzyme that is capable of splitting an OP agent or (3) scavengers that 
are able to bind to an OP and therefore decrease the level of the poisonous agent in the 
organism. (4) And in addition to the mentioned possibilities, standard oximes used as 
antidotes exert prophylactic effects as well (Bajgar 2004).  
 
(2) Medications 
 
There are three main classes of medication that are helpful in the management of 
intoxication: anticholinergics, oximes, and anticonvulsants.  
1.  Atropine is the classic anticholinergic drug, or more precisely 
antimuscarinic drug, recommended for the treatment of organophosphorus 
intoxications. It competitively and reversibly blocks the binding of ACh to the 
muscarinic receptor but has no significant effects at nicotinic receptors. This means that 
it is an effective treatment of parasympathetically mediated effects on excessive 
secretions and smooth muscle activation caused by nerve agents, but which can not treat 
muscle paralyis (Cannard 2006). 
2.  While atropine helps reverse the effects of parasympathetic overload, 
AChE reactivators such as one of the recommended pyridinium oximes (pralidoxime, 
trimedoxime, HI-6, obidoxime, methoxime) are used for the treatment of 
organophosphate poisoning in humans by restoring the AChE activity the function of 
the NMJ. However, oximes are only effective before aging. The rate of aging is 
different for each NA. The half-time of aging for soman is only 2-6 min (Sidell and 
Groff 1974), therefore they are theoretically useless in soman exposures. Since oximes 
reactivate AChE, one might expect a global reversal of all effects, but in practice, they 
have little effect on muscarinic symptoms and signs (Cannard 2006). 
3.  The likelihood of convulsions is directly related to the dose of exposure. 
Diazepam is currently the anticonvulsant of choice for the treatment of prolonged 
seizures or the status epilepticus. A reduction in mortality of NA-exposed experimental 
animals treated with diazepam has been demonstrated, particulary when used in 
combination with atropine (Cannard 2006).  
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E. Acetylcholinesterase Reactivators 
 
Although the phosporylated esteric site of AChE undergoes hydrolytic regeneration at a 
slow or negligible rate, Wilson (1951) found that nucleophilic agents, such as 
hydroxylamine (NH2OH), hydroxamic acids (RCONH-OH) and oximes (RCH=NOH), 
reactivate the enzyme more rapidly than does the spontaneous hydrolysis. Selective 
reactivation is achieved by a site-directed nucleophile, where the interaction of a 
quaternary nitrogen with the negative subsite of the active center would place the 
nucleophile in close apposition to the phosphorus. Wilson and Ginsburg (1955) proved 
that with pyridine-2-aldoxime methyl chloride (pralidoxim) occurs the reactivation at a 
million times the rate of that with hydroxylamine (Goodman and Brunton 2008). The 
oxime moiety is oriented proximally to exert a nucleophilic attack on the phosphorus; a 
phosphoryloxime is formed, leaving the regenerated enzyme (Wilson 1959). Several 
bis-quaternary oximes were shown subsequently to be even more potent as reactivators 
for insecticide and nerve gas poisoning.   
 
 
1. Pyridinium Oximes 
 
 
 
Figure 6: Reactivation of phosphorylated acetylcholinesterase with pralidoxime and 
formation of reactivated enzyme and phosphorylated oxime  
 
Besides their reactivation potency, oximes bind to AChE as reversible inhibitors, form 
complexes with AChE (either in the active site or in the allosteric site or in both sites of 
the enzyme) and protect AChE from phosphorylation. When the reversible inhibitor 
binds to the active site, the protection is due to direct competition between the 
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organophosphorus compound and reversible inhibitor. Binding of a reversible inhibitor 
to the allosteric site induces indirect protection of the active site (Jokanovic and 
Stojiljkovic 2006). For oximes, the plasma concentration of 4 μl/ml is generally 
accepted as the minimum to counteract nerve poisoning (Kassa 2002). 
 
 
2. Pyridinium oximes used in the treatment of OPC 
poisoning 
 
We can divide them into two groups — the monopyridinium and bispyridinium oximes. 
The only currently used monopyridinium oxime is pralidoxime (2-PAM), while the 
most significant bispyridinium oximes comprise: trimedoxime (TMB-4), obidoxime 
(LüH-6, Toxogonin), HI-6 and HLö-7 (Dawson 1994). HI-6 is considered to be the 
most versatile reactivator, however its reactivation potency is not sufficient in the case 
of tabun poisoning. Here, obidoxime is the drug of choice as well as in the case of 
poisoning by pesticides (Jokanovic and Maksimovic 1995; Kassa 2002). 
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Figure 7: Commonly used oxime reactivators 
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Figure 8: New promissing compounds 
 
 
 
a) Pralidoxime (2-PAM) 
 
Pralidoxime was synthesised in the USA in 1955 (Wilson and Ginsburg 1955) and is 
very efficient in reactivating of AChE inhibited with sarin or VX (Sidell and Groff 
1974; Nozaki, Aikawa et al. 1995), but was not successful in reactivation of the tabun- 
or soman-inhibited enzyme (Koplovitz and Stewart 1994). 2-PAM, as quaternary 
pyridinium salt, does not easily penetrate the blood–brain barrier into the central 
nervous system. 
 
b) Trimedoxime (TMB-4) 
 
It is the only of the major bispyridinium oximes with a propylene bridge between the 
two pyridinium rings. It was shown that TMB-4 is a more potent reactivator of the DFP-
inhibited AChE than 2-PAM (Hobbiger and Sadler 1958) and better reactivator than 
LüH-6 in the case of the tabun-inhibited enzyme.  
 
c) Obidoxime (LüH-6, Toxogonin) 
 
Obidoxim was synthesised in Germany and introduced into medical practice in 1964 . 
The new oxime showed immediately a significant potential as an antidote in poisonings 
with OPCs (Erdmann and Engelhard 1964). Similarly to 2-PAM and TMB-4, LüH-6 
was also inefficient in soman poisoning in primates (Hamilton and Lundy 1989). 
 
27 
d) HI-6 
 
The first oxime that could reactivate soman-inhibited AChE and afford at least some 
protection of the animals experimentally poisoned with this nerve agent (Inns and 
Leadbeater 1983). The only drawback of HI-6 was that this oxime could not reactivate 
tabun-inhibited AChE (Clement 1982). But it still remains  the most versatile antidote 
and therefore is used as the drug of choice. 
 
e) HLö-7 
 
This latest important oxime reactivates AChE inhibited by any of the four major nerve 
agents (Worek, Kirchner et al. 1994) as well as the enzyme inhibited by cyclosarin 
(Lundy, Hansen et al. 1992).  
 
f) Newly developed oximes 
 
K027 is a very good reactivator of tabun- and methylparaoxone-inhibited AChE in both 
in vitro and in vivo experiments with relatively low toxicity (Kuca, Bartosova et al. 
2005; Petroianu, Nurulain et al. 2007). K203 is also promising compound of tabun-
inhibited AChE (Kovarik, Calic et al. 2008) and in combination with atropine seems to 
be effective for a decrease in tabun-induced neurotoxicity (Kassa, Karasova et al. 2009).  
 
 
3. Non-reactivation properties of reactivators 
 
For a long time it has been thought that, besides performing AChE reactivation in 
organophosphate poisoning, oximes might also show some direct pharmacological 
effects. This was supported by observations that in some studies the antidotal effects of 
oximes could not be explained only on the basis of AChE reactivation (Clement 1981). 
In some experiments, only limited or no reactivation of soman-inhibited cholinesterase 
activity occurred when HI-6 was administered suggesting that some other mechanism of 
action of HI-6 other than cholinesterase reactivation is partly responsible for this 
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enhanced protective activity of HI-6 (Hamilton and Lundy 1989; van Helden, van der 
Wiel et al. 1992). 
 
Many scientist wonder what kinds of mechanisms other than reactivation are involved 
in life-saving results after lethal intoxication by tabun and soman. Several models have 
been tested using different oximes and data have showed that the survival was due to a 
recovery of neuromuscular transmission in respiratory centers and in diaphragm 
(Hamilton and Lundy 1989; van Helden, van der Wiel et al. 1992). It was showed by the 
binding studies that there is a confirmed affinity of commonly used oximes to 
muscarinic receptors, similar to the nicotinic receptors. (Amitai, Kloog et al. 1980) 
Their inhibitory constants to the muscarinic receptors are in micromole range. 
 
The mechanism of binding to the muscarinic receptors is still not fully unraveled, but 
allosteric manner is a possibility. The number of allosteric binding sites is still a matter 
of discussion even though it is suggested positive and negative allosteric modulators 
bind to the same or overlapping sites (Proska and Tucek 1995). It is possible that most 
of these modulators of muscarinic receptors bind to the same site on the receptor, since 
most of these modulators decelerate the association and dissociation of ligands at the 
orthosteric site probably by obstructing the access of the ligand. It is also possible that 
some ligands bind to both orthosteric and allosteric binding sites simultaneously. The 
muscarinic M2 receptor is assumed to be more sensitive to allosteric ligands than other 
muscarinic receptor subtypes (Christopoulos, Lanzafame et al. 1998). For instance, 
obidoxim is considered to be an allosteric modulator of muscarinic M2 receptor (Ellis 
and Seidenberg 1992) or an allosteric antagonist (Grossmuller, Antony et al. 2006). 
 
 The antagonistic activity of oximes could be of importance in the search for other 
modes of actions, which may be complementary to the reactivating effect. In order to 
characterize the anticholinergic of selected oximes, the atria of the heart were chosen for 
functional examinations. In the atria, acetylcholine decreases the heart frequency by 
acting on muscarinic M2 receptors (Caulfield and Birdsall 1998). Both in vitro and in 
vivo techniques were used for examination. 
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III. Aim 
 
The aim of the thesis was to investigate whether or not ―classical‖ reactivators 
obidoxime and HI-6 and the newly synthesized compounds K027 and K203 affect 
muscarinic receptor mediated responses differently in the atria and to compare the 
effective doses. 
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IV. Materials and Methods 
 
A. Animals 
 
Male rats of the Sprague-Dawley strain with the weight of 250-400 g were used in the 
current thesis. The Ethical committee of Göteborg University approved the study. 
 
B. Materials 
 
Dormitor, Ketalar, Heparin (all Apoteket AB, Sweden), Adrenaline: phenylephrine 
(Sigma, St. Louis USA), Methacholine: 2-acetyloxypropyl-trimethyl-azanium (Sigma, 
St. Louis USA), Obidoxime(1,3-bis(4-hydroxyiminomethylpyridium)-2-oxapropane 
dichloride), HI-6(1-(2-hydroxyamino-methylpyridinium)-3-(4-carbamoylpyridinium)-2-
oxapropane dimethansulfonate), K027(1-(4-hydroxyiminomethylpyridinium)-3-(4-
carbamoylpyridinium) propanedibromi-de), K203([(E)-1-(4-carbamoylpyridinium)-4-
(4-hydroxyiminomethylpyridinium)-but-2-ene dibromide) were synthesized at the 
Department of Toxicology, Faculty of Military Health Science, University of Defence, 
Hradec Králové, Czech Republic.  
 
C. Data Analysis 
 
The tension was measured by MP100WSW data acquisition system (Biopac Systems, 
Goleta, CA, US) recorded and analysed on computer using the ACQ knowledge 
software (version 3.7.2 Biopac). Calculations were performed using Microsoft Excel 
2000 and statistics were made by GraphPad Prism (version 4.01, GraphPad Software 
Inc.). 
All data values are expressed as mean±s.e.m. Statistical significance was determined by 
one-way or two-way analysis of variance (ANOVA) followed by the Bonferroni 
multiple-comparison test. All statistical analyses were performed on raw data, but the 
graphs are presented in percentages. P-values of 0.05 or less were regarded as 
statistically significant.  
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D. In vitro studies 
 
The rats were killed with carbon dioxide with premedication of Dormitor (medetomidin 
hydrochlorid 0,5mg/kg I.P.) and the organs (heart atria) were cut off the animals and 
fixed into the organ baths. It is necessary to keep them dry in sufficient amount of Krebs 
solution.  The tissues were attached via a thread to isometric force transducer consisting 
of two steel rods where one is fixed and the other is adjustable. Each organ bath is filled 
with 25 ml of Krebs bicarbonate solution containing: NaCl 118 mM, KCl 4.6 mM, 
CaCl2 1.25 mM, KH2PO4 1.15 mM, MgSO4 1.15 mM, NaHCO3 25 mM, and glucose 
5.5 mM, bubbled by gas mixture of 95% O2 and 5% CO2. The temperature was kept at 
37 ºC by a thermostat and pH = 7.4. 
Krebs solution was prepared from deionised water, NaCl 6.9g/l, KCl 0.34g/l, KH2PO4 
0.16g/l, MgSO4 0.14g/l, NaHCO3 2.10g/l, glucose 0.99g/l, the solution was bubbled by 
gas mixture of 95% O2 and 5% CO2 for at least 45 minutes before CaCl2 0.18g/l was 
added and then it was bubbled by the same gas throughout the experiment to keep the 
stable neutral pH. All drugs additions were performed using a volume of 125 µl. 
 
 
1. Atrial preparation 
 
The heart was isolated and an atrial strip was prepared. The atria were placed on a 
bipolar electrode consisting of 3 rods – first one was the strip holder and second two 
provided the electrical stimulation from the stimulator. Atria were at the same time 
fastened to the adjustable rod to record changes in tension. The tension was adjusted 
during the stabilizing period of 30 minutes to a level of 4-7 mN. After stabilization, the 
atria were stimulated at 1 Hz at supramaximal voltage (50 V), delivered as square wave 
pulses with duration of 0.8 ms (stimulator: STM 100C, Linton, Welwyn Garden City, 
UK). Later, the doses of adrenaline and methacholine both in volume of 125 µl to reach 
the concentration of 10
-4
 M in the bath were administered. Then the increasing doses of 
oximes in concentration of 10
-7 
to 10
-4
 were administered in 10 minutes intervals in 
order to determine their antimuscarinic qualities as acetylcholinesterase reactivators.  
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2. Protocol for atria 
 
1. Start recording on the computer 
2. Turn on the continuous stimulation (1 Hz) 
3. Waiting until a stable recording is reached 
4. Add 125 µl of adrenaline at appropriate concentration to get 10-4 M in the bath 
5. Wait until it gets stabilized 
6. Add 125 µl of metacholine at appropriate concentration to get 10-4 M 
7. After stabilization add 125 µl of appropriate increasing concentration of oximes 
(K027, K203, HI-6, Obidoxime) to obtain 10
-7
, 10
-6
, 10
-5
, 10
-4
 M in each bath 
8. Switch the continuous stimulation off 
 
 
E. In vivo studies  
 
The preparatory methods were generally described previously by Tobin. G et al. (Tobin 
and Sjogren 1995).  
 
The rats were anaesthetized with Dormitor (35mg/kg I.P.) and Ketalar i.m. 
(50mg/kg I.M.). During the experiment the Dormitor was infused via the femoral vein 
for maintenance of anaesthesia, when necessary. The body temperature was kept at 
37°C by means of a thermostatically controlled blanket connected to a thermister 
inserted into the rectum. The arterial blood pressure and heart rate were monitored 
continuously via a catheter inserted into the femoral artery. The catheter was filled with 
saline and small amount of heparine. Barometer used in the experiment was calibrated. 
For maintaining a free airway, a cannula was placed in the trachea of the rat after 
tracheotomy. The left vagal nerve was exposed in the neck and a bipolar electrode 
placed under the nerve. Sympathetic nerve fibres running in close contact with vagal 
nerve were identified and cut. To prevent afferent activation, the vagal nerve was cut 
coronally. The muscarinic activation was performed by electrical stimulation of the 
vagal nerve (10 Hz, 8 V square-wave; 2 msec pulse-width).  
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After reaching the stable basal blood pressure reading, an increasing dose of the oximes 
was administered through the femoral vein. The doses of the drug used were 10µg/kg, 
100µg/kg, 1mg/kg, 10mg/kg respectively. The animals were killed with an overdose of 
dormitor at the end of the experiments. Recordings were recorded externally, using 
pressure transducer (Biopac Systems, Goleta, CA, US) and evaluated by the software 
ACQ Acknowledge (Biopac Systems, Goleta, CA, US). 
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V. Results 
 
In the anaesthetized rats, the basal heart frequency was 380±31 bpm (n=23) before 
application of any experimental procedure. At the onset of electrical stimulation of the 
vagal nerve at 10 Hz, the heart frequency dropped to 312±27 bpm (n=23; p<0.01). The 
decrease in the heart frequency was more pronounced by HI-6 and obidoxime in 
comparison with K203 and K027. 
The reduction of heart frequency in response to the ongoing electrical stimulation was 
dose-dependently inhibited by the administration of any of the four oximes. The 
maximum inhibition of the frequency decrease cause by the vagal stimulation was at 
100 µg/kg i.v. by HI-6 (n=5; -12±3%; p<0.01), K027 (n=5; 100±1% of basal frequency; 
p<0.001) and obidoxime, while the maximum inhibition by K203 occurred at 1 mg/kg 
i.v. (n=5; 110±4% of basal frequency; p<0.001) although the dose of 100 µg/kg i.v 
already caused inhibition with p<0.001 (n=5).  
 
A. In vivo effects on heart frequency 
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Figure 9: The effect of obidoxim on BPM in the anesthetized rat. Changes in heart 
frequency in anaesthetized rats in the absence and presence of reactivators during the 
vagal stimulation. Star indicates statistical significance: *(p<0.05). Horizontal bar 
indicates the stimulation. All values are expressed as mean±s.e.m. 
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Figure 10: The effect of HI-6 on BPM in the anesthetized rat. Changes in heart 
frequency in anaesthetized rats in the absence and presence of reactivators during the 
vagal stimulation. Stars indicate statistical significance: *(p<0.05) **(p<0.01). 
Horizontal bar indicates the stimulation. All values are expressed as mean±s.e.m. 
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Figure 11: The effect of K203 on BPM in the anesthetized rat. Changes in heart 
frequency in anaesthetized rats in the absence and presence of reactivators during the 
vagal stimulation. Stars indicate statistical significance: ***(p<0.001) Horizontal bar 
indicates the stimulation. All values are expressed as mean±s.e.m. 
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Figure 12: The effect of K027 on BPM in the anesthetized rat. Changes in heart 
frequency in anaesthetized rats in the absence and presence of reactivators during the 
vagal stimulation. Stars indicate statistical significance: *(p<0.05) **(p<0.01) 
***(p<0.001) Horizontal bar indicates the stimulation. All values are expressed as 
mean±s.e.m. 
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B. In vitro effects on atrial frequency 
 
The spontaneous (supported by a low electrical stimulation 0.1 Hz), basal frequency 
of isolated atrial preparations amounted to 492±37 (n=20) bpm. The experiments were 
performed in the presence of adrenaline (10
-4
 M) to response of which all other 
responders are normalized. The administration of adrenaline at 10
-4
 M increased the 
frequency to 535±18 bpm (n=20; p<0.05). Methacholine at 10-4 M reduced the 
frequency in all groups ((-13±3% (p<0.01), -12±1% (p<0.001), -12±2% (p<0.05) - 
31±2% (p<0.01) in the HI-6, K203, K027 and obidoxime group, respectively (n=5 in 
each group)). The addition of the oximes causes a dose-dependent increases in the atrial 
frequency. While HI-6 eliminated the methacholine induced frequency decrease at 10
-6
 
M, K203 and K027 caused the same elimination at 10
-4
 M unlike by obidoxime where 
the response at any dose never reached the frequency before the addition of 
methacholine. 
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Figure 13: The effect of obidoxime on BPM in the isolated atria. Adr stands for 
adrenaline, MCh for methacholine. Horizontal arrows indicate the presence of drugs in 
the organ bath. Changes in frequency of isolated atrial preparations in the absence and 
presence of reactivators during chemical stimulation by methacholine (10
-4
 M). All 
values are expressed as mean±s.e.m. The star indicates the statistical significance: 
*(p<0.05). 
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Figure 14: The effect of obidoxime on BPM in the isolated atria. Horizontal arrows 
indicate the presence of drugs in the organ bath. Changes in frequency of isolated atrial 
preparations in the absence and presence of reactivators during chemical stimulation by 
methacholine (10
-4
 M). All values are expressed as mean±s.e.m. Stars indicate the 
statistical significance: **(p<0.01). 
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Figure 15: The effect of obidoxime on BPM in the isolated atria. Horizontal arrows 
indicate the presence of drugs in the organ bath. Changes in frequency of isolated atrial 
preparations in the absence and presence of reactivators during chemical stimulation by 
methacholine (10
-4
 M). All values are expressed as mean±s.e.m. Stars indicate the 
statistical significance: *(p<0.05) **(p<0.01). 
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Figure 16: The effect of K203 on BPM in the isolated atria. Horizontal arrows indicate 
the presence of drugs in the organ bath. Changes in frequency of isolated atrial 
preparations in the absence and presence of reactivators during chemical stimulation by 
methacholine (10
-4
 M). All values are expressed as mean±s.e.m. Stars indicate the 
statistical significance: ***(p<0.001). 
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VI. Discussion 
 
 
Oximes are compounds designed to reactivate acetylcholinesterase, which 
becomes inactive due to the inhibition via phosphorylation or phosphonylation of serine 
hydroxyl group at its active site by organophosphorus compounds such as tabun, sarin, 
soman, cyclosarin or parathion (Goodman and Brunton 2008). Reactivating properties 
have already been tested and proved (Wilson 1959) several decades ago. Nowadays, 
further experiments are trying to unreveal non-reactivating properties of oximes 
(Tattersall 1993; van Helden, Busker et al. 1996). These include various effects of 
oximes such as actions on muscarinic ACh-receptors and effects on ion-channels 
associated with the nicotinic ACh-receptors (van Helden, Busker et al. 1996).  
 
This study was designed to show the effect of AChE reactivators on the 
muscarinic receptors, i.e. non-reactivating property of oximes. Rat atria have been 
chosen as the model tissue, where M2 receptors occur so their influence on the heart 
rate could be examined. M2-receptor activation is responsible for the vagal inhibition of 
the heart rate (Rang and Dale 2007). The frequency has been examined by both in vitro 
and in vivo techniques.  
 
During the in vitro experiments, the atrial preparations were exposed to a low 
frequency stimulation to provoke spontaneous activity. In order to enhance the 
possibility of cholinergic effects on the atrial frequency, adrenaline was added initially. 
Adrenaline is a non selective agonist of all adrenergic receptors and in the body 
basically acts against ACh, concretely increases heart rate (Goodman and Brunton 
2008). Thereafter, methacholine, a muscarinic agonist, was administered as a reference 
of maximal receptor response. All compounds exerted an antimuscarinic effect, i.e. all 
oximes re-increased methacholine-decreased heart frequency. Response for adrenaline 
was taken as 100% and all other responces referred to this value. First concentration of 
K027, which reached the statistical significance was 1 μM and with every higher 
concentration increased even more up to proximately 110% of the basal frequency. That 
was the highest increase in frequency of all tested oximes. In the case of K203, the 
frequency was also slightly increasing above 100% - the maximum was at the 1 mM. It 
should be pointed out, that blocking effect of any compound probably should not cause 
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exceeding of 100%, so other mechanism like symphatetic stimulation may occurred, but 
more probably this was only due to variation of results and small number experiments. 
In case of K203 the first significantly effective dose was 10 µM, the significant effect at 
0.1 µM might be only an artifact since we could expect some higher variation in the 
lower concentrations. HI-6 seems to be very effective, already at the lowest tested 
concentration (0.1 µM) with the maximum at 1 µM and then very slightly decreasing. 
This could be caused by the higher affinity HI-6 towards the enzyme and its inhibition 
with the higher concentration of oxime (Bajgar 2004). Although, in the study where 
inhibition constants were determined, HI-6 showed similar potency to inhibit the 
enzyme as K203 (Sinko, Brglez et al. 2010). 
Also already the lowest tested dose of obidoxime, 0.1 µM, displayed its 
antimuscarinic effect (the significant effect at 1 µM can be again taken as an artifact). 
Although further increase in dose also increased the heart frequency but it hardly 
reached 80% of the response for adrenaline. In this respect, obidoxime could be 
regarded as a weaker muscarinic antagonist. However obidoxime has been reported as a 
weak muscarinic antagonist but usually stronger that other oxime reactivators (van 
Helden 1996).   
The main aim of this study was to give the answer whether the oximes affect 
muscarinic receptors or not. The results comfirmed the hypothesis and this finding 
supports previous experiment with obidoxime where obidoxime has been reported as an 
allosteric modulator of muscarinic M2 receptor (Ellis and Seidenberg 1992).  
The possibility of the release of acetylcholine from the cholinergic nerves by the 
oximes themselves was another question which was raised in relations with their non-
reactivating effects. (Aas 1996) showed that neither obidoxime nor HI-6 but only Hlö-7 
had a direct enhancing effect on the release of acetylcholine through activation or 
opening of Ca
2+
 channels. Thus, we could expect that neither our in vitro experiments 
were influenced by this effect, at least not in the case of obidoxime and HI-6.  
 
In vivo experimens, since vagal afferent stimulation reduces the heart rate in the 
anaesthetized rat (Saleh, Saleh et al. 2001) it was cut coronally to the point of 
stimulation which could lead to the elimination of afferent effects reduced variations in 
the results, probably by reducing the impact of compensatory mechanisms. 
According to our observations, two contradictory effects could be observed. During the 
first phase, low dose of oximes caused an inhibition of the vagal effect on heart 
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frequency (vagal stimulation reduces the heart rate) by blocking muscarinic M2 
receptors, which led to the increase in heart frequency. However, with the even more 
increased doses of oximes we could distinguish a phase, where the heart frequency 
decreased again. This phase was probably due to the inhibition of AChE. In other 
words, ACh, endogenously released by the vagal stimulation, could not be decomposed 
by the enzyme, was thus cumulated and caused the bradycardia. Comparable effect was 
described in the experiment, where oxime HGG-12 was tested in porcine cardiac atrial 
membranes (Reithmann, Berger et al. 1991). Although different method was used 
(competition binding experiment), the results show that the oxime is competetive 
antagonist without intrinsic activity at muscarinic receptors. The stimulatory action of 
HGG-12 on muscarinic acetylcholine receptors was, similar to our case, suggested to be 
due to partial inhibition of acetylcholinesterase by the oxime rather than to direct 
agonism at muscarinic acetylcholine receptors. 
Nevertheless, this dual effect could not be observed in the in vitro experiments. 
This was probably due to the fact, that methacholine used as the cholinergic stimulator 
during the in vitro experiments was only poorly broken down by AChE and its actions 
are more prolonged (Martindale and Westcott 2008).  
Comparing the individual compounds tested in vivo, muscarinic blocking 
properties can be reached already at the dose of 10 µg per kg only by K027, which is the 
lowest from all four oximes. Almost all compounds have the maximum effect on the 
muscarinic receptors at the dose of 100 micrograms per kg. The frequency decrease 
caused probably by the enzyme inhibition followed after this peak, however, it was not 
so pronounced by the oxime K203. This might be due to a lower affinity to AChE of 
this compound. This finding together with excellent reactivation potency in tabun 
poisoning and moderate toxicity (Kovarik, Vrdoljak et al. 2009) is making K203 a very 
promising antidote in organophosphorus poisoning especially caused by tabun. 
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VII. Conclusion 
 
All four tested oximes showed antimuscarinic properties. The results also showed that it 
is only matter of concentration and dose of the reactivator what makes the difference 
between muscarinic receptor antagonism and esterase inhibition. These findings 
supported the hypothesis that besides reactivation potency, oxime reactivators have 
some other, non-AChE-reactivating, effects that might be of importance in the treatment 
of organophosphorus poisoning. These effects, especially the anticholinergic properties, 
are still matter of discussion and further investigation is needed in order to characterize 
and quantify them.   
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VIII. Závěr 
 
 
Všechny čtyři testované oximy se prokázaly antimuskarinovými vlastnostmi. Výsledky 
také ukazují, že závisí pouze na koncentraci a dávce daného reaktivátoru, zda převáží 
antagonismus na muskarinovém receptoru, nebo dojde k inhibici esterázy. Tyto nálezy 
podporují hypotézu, podle které kromě reaktivace enzymu mají oximy nějaké další 
účinky, nezávislé na AChE reaktivaci. Ty by mohly být důležité v léčbě otrav 
organofosfáty. Tyto účinky, zvláště pak anticholinergní vlastnosti, jsou stále předmětem 
diskuze a je potřeba dalšího výzkumu, aby bylo možno je charakterizovat a 
kvantifikovat.  
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IX. Abbreviations 
 
ACh – acetylcholine 
AChE – acetylcholinesterase 
ATP - adenosine triphosphate 
BuChE – butyrylcholinesterase  
cAMP – cyclic adenosine monophosphate  
CarbE - carboxyesterase 
ChE – cholinoesterase 
CN – nitril 
CNS – central nervous system 
DFP - diisopropyl fluorophosphate 
LD50 - median lethal dose 
mAChR – muscarinic receptors 
NA – nerve agent 
nAChR – nicotinic receptors 
NANC – non-adrenergic non-cholinergic 
NMJ – neuromuscular junction 
NO – nitric oxide 
OP – organophosphorus 
OPC – organophosphorus compound 
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